You are here
- Home
- Drug Products
- All Drug Products
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea
- Disease
- diabetes type 2
- Drug Name
- dapagliflozin
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IIIb
- Start Date
- Jan 18, 1971
- Study Name
- D1693C00005
- Study Id
- D1693C00005
- ClinicalTrials.gov ID
- NCT01392677
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
